The 35 patients included 28 (28/35, 80.0%) patients with AML, not otherwise specified (AML, NOS), 5 (5/35, 14.3%) patients with AML with myelodysplasia-related changes (AML-MRC), 1 (1/35, 2.9%) patient with AML with t(8;21)(q22;q22.1)/RUNX1-RUNX1T1 and 1 (1/35, 2.9%) patient with AML with inv (16)(p13.1q22)/CBFβ-MYH11(concurrent with a KIT mutation). This evidence concerns the gene RUNX1 and acute myeloid leukemia.